Abstract
Sudden cardiac death (SCD) is among the most common causes of death in developed countries throughout the world. Despite decreased overall cardiac mortality, SCD rates appear to be increasing in concert with escalating global prevalence of coronary disease and heart failure, the two major conditions predisposing to SCD. This unfavorable trend is a consequence of our inability to identify those who will die suddenly from lethal ventricular arrhythmias and to develop effective therapies for all populations at risk. The known risk factors for SCD lack the predictive power needed to generate preventive strategies for the large number of fatal arrhythmic events that occur among lower-risk subsets of the population. Even among recognized high-risk subsets, prediction of SCD remains challenging. With the exception of the implantable cardioverter defibrillator (ICD) there are few effective strategies for the prevention and treatment of SCD. This article discusses the prospect of genomic science as an approach to the identification of patients at high-risk for SCD. While the final common pathway for SCD is malignant ventricular arrhythmias, there are many potential contributors, pathways, and mechanisms by which common genetic variants (polymorphisms) could affect initiation and propagation of life-threatening cardiac arrhythmias. Recent advances in genomic medicine now provide us with novel approaches to both identify candidate genes/pathways and relatively common polymorphisms which may predispose patients to increased risk for SCD. Improved understanding of the relationship between common polymorphisms and SCD will not only improve risk stratification such that ICDs can be targeted to those patients most likely to benefit from them but also provide new insight into the pathophysiology of SCD.
Similar content being viewed by others
References
Association AH (2006) Heart disease and stroke statistics—2006 update. American Heart Association, Dallas, TX
Ho KK, Anderson KM, Kannel WB, Grossman W, Levy D (1993) Survival after the onset of congestive heart failure in Framingham heart study subjects. Circulation 88:107–115
Goldman S, Johnson G, Cohn JN, Cintron G, Smith R, Francis G (1993) Mechanism of death in heart failure. The vasodilator-heart failure trials. The V-HeFT VA cooperative studies group. Circulation 87:VI24–VI31
Narang R, Cleland JG, Erhardt L et al (1996) Mode of death in chronic heart failure. A request and proposition for more accurate classification. Eur Heart J 17:1390–1403
Kannel WB, Plehn JF, Cupples LA (1988) Cardiac failure and sudden death in the Framingham study. Am Heart J 115:869–875
Moss AJ, Hall WJ, Cannom DS et al (1996) Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter automatic defibrillator implantation trial investigators. N Engl J Med 335:1933–1940
Buxton AE, Lee KL, Fisher JD, Josephson ME, Prystowsky EN, Hafley G (1999) A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter unsustained tachycardia trial investigators. N Engl J Med 341:1882–1890
Moss AJ, Zareba W, Hall WJ et al (2002) Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 346:877–883
Bardy GH, Lee KL, Mark DB et al (2005) Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 352:225–237
Josephson M, Wellens HJ (2004) Implantable defibrillators and sudden cardiac death. Circulation 109:2685–2691
Zipes DP, Wellens HJ (1998) Sudden cardiac death. Circulation 98:2334–2351
Yang P, Kanki H, Drolet B et al (2002) Allelic variants in long-QT disease genes in patients with drug-associated torsades de pointes. Circulation 105:1943–1948
Roden DM (1998) Taking the “idio” out of “idiosyncratic”: predicting torsades de pointes. Pacing Clin Electrophysiol 21:1029–1034
Splawski I, Timothy KW, Tateyama M et al (2002) Variant of SCN5A sodium channel implicated in risk of cardiac arrhythmia. Science 297:1333–1336
Schwartz PJ, Vanoli E, Stramba-Badiale M, De Ferrari GM, Billman GE, Foreman RD (1988) Autonomic mechanisms and sudden death. New insights from analysis of baroreceptor reflexes in conscious dogs with and without a myocardial infarction. Circulation 78:969–979
Tomaselli GF, Zipes DP (2004) What causes sudden death in heart failure? Circ Res 95:754–763
Chen PS, Chen LS, Cao JM, Sharifi B, Karagueuzian HS, Fishbein MC (2001) Sympathetic nerve sprouting, electrical remodeling and the mechanisms of sudden cardiac death. Cardiovasc Res 50:409–416
Small KM, McGraw DW, Liggett SB (2003) Pharmacology and physiology of human adrenergic receptor polymorphisms. Ann Rev Pharmacol Toxicol 43:381–411 Epub 2002 Jan 10
Liggett SB (2004) Genetically modified mouse models for pharmacogenomic research. Nat Rev Genet 5:657–663
Drummond GA, Squire IB (1999) The cardiac insufficiency bisoprolol study II. Lancet 353:1361
Merit-HF Study Group (1999) Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomised intervention trial in congestive heart failure (MERIT-HF). Lancet 353:2001–2007
Packer M, Bristow MR, Cohn JN et al (1996) The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. US carvedilol heart failure study group. N Engl J Med 334:1349–1355
Levin MC, Marullo S, Muntaner O, Andersson B, Magnusson Y (2002) The myocardium-protective Gly-49 variant of the beta 1-adrenergic receptor exhibits constitutive activity and increased desensitization and down-regulation. J Biol Chem 277:30429–30435
Ranade K, Jorgenson E, Sheu WH et al (2002) A polymorphism in the beta1 adrenergic receptor is associated with resting heart rate. Am J Hum Genet 70:935–942
Borjesson M, Magnusson Y, Hjalmarson A, Andersson B (2000) A novel polymorphism in the gene coding for the beta(1)-adrenergic receptor associated with survival in patients with heart failure. Eur Heart J 21:1853–1858
Mason DA, Moore JD, Green SA, Liggett SB (1999) A gain-of-function polymorphism in a G-protein coupling domain of the human beta1-adrenergic receptor. J Biol Chem 274:12670–12674
Liggett SB, Mialet-Perez J, Thaneemit-Chen S et al (2006) A polymorphism within a conserved beta(1)-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure. Proc Natl Acad Sci USA 103:11288–11293
Green SA, Cole G, Jacinto M, Innis M, Liggett SB (1993) A polymorphism of the human beta 2-adrenergic receptor within the fourth transmembrane domain alters ligand binding and functional properties of the receptor. J Biol Chem 268:23116–23121
Green SA, Turki J, Innis M, Liggett SB (1994) Amino-terminal polymorphisms of the human beta 2-adrenergic receptor impart distinct agonist-promoted regulatory properties. Biochemistry 33:9414–9419
Sotoodehnia N, Siscovick DS, Vatta M et al (2006) Beta2-adrenergic receptor genetic variants and risk of sudden cardiac death. Circulation 113:1842–1848
Liggett SB (2006) Beta2-adrenergic receptor polymorphisms and sudden cardiac death: a signal to follow. Circulation 113:1818–1820
Pitt B, Zannad F, Remme WJ et al (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators. N Engl J Med 341:709–717
Sleight P (2002) Angiotensin II and trials of cardiovascular outcomes. Am J Cardiol 89:11A–16A; discussion 16A–17A
Domanski MJ, Exner DV, Borkowf CB, Geller NL, Rosenberg Y, Pfeffer MA (1999) Effect of angiotensin converting enzyme inhibition on sudden cardiac death in patients following acute myocardial infarction. A meta-analysis of randomized clinical trials. J Am Coll Cardiol 33:598–604
Seidman JG, Seidman C (2001) The genetic basis for cardiomyopathy: from mutation identification to mechanistic paradigms. Cell 104:557–567
Takeishi Y, Walsh RA (2001) Cardiac hypertrophy and failure: lessons learned from genetically engineered mice. Acta Physiol Scand 173:103–111
Lim DS, Lutucuta S, Bachireddy P et al (2001) Angiotensin II blockade reverses myocardial fibrosis in a transgenic mouse model of human hypertrophic cardiomyopathy. Circulation 103:789–791
Samani NJ, Thompson JR, O’Toole L, Channer K, Woods KL (1996) A meta-analysis of the association of the deletion allele of the angiotensin-converting enzyme gene with myocardial infarction. Circulation 94:708–712
Raynolds MV, Bristow MR, Bush EW et al (1993) Angiotensin-converting enzyme DD genotype in patients with ischaemic or idiopathic dilated cardiomyopathy. Lancet 342:1073–1075
Marian AJ, Yu QT, Workman R, Greve G, Roberts R (1993) Angiotensin-converting enzyme polymorphism in hypertrophic cardiomyopathy and sudden cardiac death. Lancet 342:1085–1086
Bedi MS, Postava LA, Murali S et al (2004) Interaction of implantable defibrillator therapy with angiotensin-converting enzyme deletion/insertion polymorphism. J Cardiovasc Electrophysiol 15:1162–1166
Pacifico A, Henry PD (2003) Structural pathways and prevention of heart failure and sudden death. J Cardiovasc Electrophysiol 14:764–775
Kanno S, Saffitz JE (2001) The role of myocardial gap junctions in electrical conduction and arrhythmogenesis. Cardiovasc Pathol 10:169–177
Spach MS, Josephson ME (1994) Initiating reentry: the role of nonuniform anisotropy in small circuits. J Cardiovasc Electrophysiol 5:182–209
Lerner DL, Yamada KA, Schuessler RB, Saffitz JE (2000) Accelerated onset and increased incidence of ventricular arrhythmias induced by ischemia in Cx43-deficient mice. Circulation 101:547–552
Gutstein DE, Morley GE, Tamaddon H et al (2001) Conduction slowing and sudden arrhythmic death in mice with cardiac-restricted inactivation of connexin43. Circ Res 88:333–339
Yao JA, Gutstein DE, Liu F, Fishman GI, Wit AL (2003) Cell coupling between ventricular myocyte pairs from connexin43-deficient murine hearts. Circ Res 93:736–743
Thompson CA, Yarzebski J, Goldberg RJ, Lessard D, Gore JM, Dalen JE (2000) Changes over time in the incidence and case-fatality rates of primary ventricular fibrillation complicating acute myocardial infarction: perspectives from the Worcester heart attack study. Am Heart J 139:1014–1021
Dekker LR, Bezzina CR, Henriques JP et al (2006) Familial sudden death is an important risk factor for primary ventricular fibrillation: a case-control study in acute myocardial infarction patients. Circulation 114:1140–1145
Gnasso A, Motti C, Irace C et al (2000) Genetic variation in human stromelysin gene promoter and common carotid geometry in healthy male subjects. Arterioscler Thromb Vasc Biol 20:1600–1605
Weiss EJ, Bray PF, Tayback M et al (1996) A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis. N Engl J Med 334:1090–1094
Mikkelsson J, Perola M, Laippala P, Penttila A, Karhunen PJ (2000) Glycoprotein IIIa Pl(A1/A2) polymorphism and sudden cardiac death. J Am Coll Cardiol 36:1317–1323
Snapir A, Mikkelsson J, Perola M, Penttila A, Scheinin M, Karhunen PJ (2003) Variation in the alpha2B-adrenoceptor gene as a risk factor for prehospital fatal myocardial infarction and sudden cardiac death. J Am Coll Cardiol 41:190–194
Anvari A, Schuster E, Gottsauner-Wolf M, Wojta J, Huber K (2001) PAI-I 4G/5G polymorphism and sudden cardiac death in patients with coronary artery disease. Thromb Res 103:103–107
Iwai N, Shimoike H, Nakamura Y, Tamaki S, Kinoshita M (1998) The 4G/5G polymorphism of the plasminogen activator inhibitor gene is associated with the time course of progression to acute coronary syndromes. Atherosclerosis 136:109–114
Wang XL, Sim AS, Wang MX, Murrell GA, Trudinger B, Wang J (2000) Genotype dependent and cigarette specific effects on endothelial nitric oxide synthase gene expression and enzyme activity. FEBS Lett 471:45–50
Nakayama M, Yasue H, Yoshimura M et al (1999) T-786—>C mutation in the 5′-flanking region of the endothelial nitric oxide synthase gene is associated with coronary spasm. Circulation 99:2864–2870
Bers DM (2002) Cardiac excitation–contraction coupling. Nature 415:198–205
Priori SG, Napolitano C, Tiso N et al (2001) Mutations in the cardiac ryanodine receptor gene (hRyR2) underlie catecholaminergic polymorphic ventricular tachycardia. Circulation 103:196–200
Terentyev D, Viatchenko-Karpinski S, Gyorke I, Volpe P, Williams SC, Gyorke S (2003) Calsequestrin determines the functional size and stability of cardiac intracellular calcium stores: mechanism for hereditary arrhythmia. Proc Natl Acad Sci USA 100:11759–11764
Lahat H, Pras E, Olender T et al (2001) A missense mutation in a highly conserved region of CASQ2 is associated with autosomal recessive catecholamine-induced polymorphic ventricular tachycardia in Bedouin families from Israel. Am J Hum Genet 69:1378–1384
Splawski I, Timothy KW, Sharpe LM et al (2004) Ca(V)1.2 calcium channel dysfunction causes a multisystem disorder including arrhythmia and autism. Cell 119:19–31
Splawski I, Timothy KW, Decher N et al (2005) Severe arrhythmia disorder caused by cardiac L-type calcium channel mutations. Proc Natl Acad Sci USA 102:8089–8096
MacLennan DH, Asahi M, Tupling AR (2003) The regulation of SERCA-type pumps by phospholamban and sarcolipin. Ann N Y Acad Sci 986:472–480
Ozaki K, Ohnishi Y, Iida A et al (2002) Functional SNPs in the lymphotoxin-alpha gene that are associated with susceptibility to myocardial infarction. Nat Genet 32:650–654
Samani NJ, Erdmann J, Hall AS et al (2007) Genomewide association analysis of coronary artery disease. N Engl J Med 357:443–453
Gudbjartsson DF, Arnar DO, Helgadottir A et al (2007) Variants conferring risk of atrial fibrillation on chromosome 4q25. Nature 448(7151):353–357
Arking DE, Pfeufer A, Post W et al (2006) A common genetic variant in the NOS1 regulator NOS1AP modulates cardiac repolarization. Nat Genet 38:644–651
Newton-Cheh C, Larson MG, Corey DC et al (2005) QT interval is a heritable quantitative trait with evidence of linkage to chromosome 3 in a genome-wide linkage analysis: the Framingham heart study. Heart Rhythm 2:277–284
Baum AE, Akula N, Cabanero M et al (2008) A genome-wide association study implicates diacylglycerol kinase eta (DGKH) and several other genes in the etiology of bipolar disorder. Mol Psychiatry 13:197–207
Acknowledgment
This work was supported in part by NIH grants HL75266, HL85690, and U01 HL65962.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Darbar, D. Genomics, heart failure and sudden cardiac death. Heart Fail Rev 15, 229–238 (2010). https://doi.org/10.1007/s10741-008-9095-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10741-008-9095-9